Optimizing outcomes for paediatric atopic dermatitis

British Journal of Dermatology

Volumn 170, Issue SUPPL. 1, 2014, Pages 31-37

  Eichenfield, L F ^a,b   Totri, C ^a,b  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLOMETASONE; ATAPRO; AURSTAT; BORIC ACID; CALCINEURIN INHIBITOR; CEFALEXIN; CHLORINE; CLN BODY WASH; CLOBETASONE BUTYRATE; CORTICOSTEROID; DESONIDE; EMOLLIENT AGENT; FLUOCINOLONE; FLUOCINOLONE ACETONIDE; FLUTICASONE; FLUTICASONE PROPIONATE; HYDROCORTISONE; HYDROCORTISONE BUTYRATE; HYPOCHLORITE SODIUM; LIPID; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; PREDNICARBATE; TACROLIMUS; TRIAMCINOLONE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; DEPIGMENTING AGENT; FILAGGRIN; INTERMEDIATE FILAMENT PROTEIN;

ACNE; ATOPIC DERMATITIS; BACTERIAL SKIN DISEASE; BACTERIUM CULTURE; BLEACHING; CHILD; COMORBIDITY; CREAM; DRUG ERUPTION; DRUG SAFETY; GENE MUTATION; GROWTH RETARDATION; HUMAN; HYDROGEL; INDUSTRIALIZATION; LOTION; MEDICINE; MICROBIAL COLONIZATION; MICROBIAL COMMUNITY; MULTICENTER STUDY (TOPIC); PATHOGENESIS; PATIENT EDUCATION; PERIORAL DERMATITIS; PERMEABILITY BARRIER; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; ROSACEA; SEXUAL MATURATION; SKIN ATROPHY; STAPHYLOCOCCUS AUREUS; STRIA; SWIMMING; SWIMMING POOL; TOPICAL TREATMENT; TREATMENT OUTCOME; TREATMENT REFUSAL; COMPLICATION; DERMATITIS, ATOPIC; GENETICS; HYDROTHERAPY; INTRADERMAL DRUG ADMINISTRATION; MEDICATION COMPLIANCE; MUTATION; PROCEDURES; SKIN INFECTION;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; CALCINEURIN INHIBITORS; CHILD; DERMATITIS, ATOPIC; HUMANS; HYDROTHERAPY; INTERMEDIATE FILAMENT PROTEINS; MEDICATION ADHERENCE; MUTATION; PATIENT EDUCATION AS TOPIC; SKIN DISEASES, INFECTIOUS; SKIN LIGHTENING PREPARATIONS; SODIUM HYPOCHLORITE; TREATMENT OUTCOME;

EID: 84902802782     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12976     Document Type: Review

References (47)

1. Saito H,. Much atopy about the skin: genome-wide molecular analysis of atopic eczema. Int Arch Allergy Immunol 2005; 137: 319-25.
2. Schmitt J, Williams H, HOME Development Group. Harmonising Outcome Measures for Eczema (HOME). Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany. Br J Dermatol 2010; 163: 1166-8.
3. Sandilands A, Sutherland C, Irvine AD, McLean WH,. Filaggrin in the frontline: role in skin barrier function and disease. J Cell Sci 2009; 122: 1285-94.
4. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al,. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-6.
5. McLean WH, Irvine AD,. Heritable filaggrin disorders: the paradigm of atopic dermatitis. J Invest Dermatol 2012; 132: E20-1.
6. Margolis DJ, Apter AJ, Gupta J, et al,. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. J Allergy Clin Immunol 2012; 130: 912-17.
7. Mayo Clinic. Atopic dermatitis (eczema) [WWW document]. Available at: http://www.mayoclinic.com/health/eczema/DS00986/DSECTION=prevention [accessed on 23 October 2013].
8. National Jewish Health. Atopic dermatitis (eczema): Lifestyle Management [WWW document]. Available at: http://www.nationaljewish.org/healthinfo/ conditions/allergy/types/eczema/lifestyle-management/soak-and-seal/ [accessed on 23 October 2013].
9. Chiang C, Eichenfield LF,. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. Pediatr Dermatol 2009; 26: 273-8.
10. Grice EA, Kong HH, Conlan S, et al,. Topographical and temporal diversity of the human skin microbiome. Science 2009; 324: 1190-2.
11. Kong HH, Segre JA,. Skin microbiome: looking back to move forward. J Invest Dermatol 2012; 132: 933-9.
12. Oh J, Conlan S, Polley EC, et al,. Shifts in human skin and nares microbiota of healthy children and adults. Genome Med 2012; 4: 77.
13. van der Aa LB, Heymans HS, van Aalderen WM, Sprikkelman AB,. Probiotics and prebiotics in atopic dermatitis: review of the theoretical background and clinical evidence. Pediatr Allergy Immunol 2010; 21: e355-67.
14. Yaghmaie P, Koudelka CW, Simpson EL,. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 2013; 131: 428-33.
15. Schmitt J, Romanos M, Schmitt NM, et al,. Atopic eczema and attention-deficit/hyperactivity disorder in a population-based sample of children and adolescents. JAMA 2009; 301: 724-6.
16. Deckert S, Kopkow C, Schmitt J,. Nonallergic comorbidities of atopic eczema: an overview of systematic reviews. Allergy 2014; 69: 37-45.
17. Huang JT, Abrams M, Tlougan B, et al,. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 2009; 123: e808-14.
18. Feldman SR, Camacho FT, Krejci-Manwaring J, et al,. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007; 57: 81-3.
19. Krejci-Manwaring J, Tusa MG, Carroll C, et al,. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007; 56: 211-16.
20. Charman CR, Morris AD, Williams HC,. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931-6.
21. Callen J, Chamlin S, Eichenfield LF, et al,. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007; 156: 203-21.
22. Hong E, Smith S, Fischer G,. Evaluation of the atrophogenic potential of topical corticosteroids in pediatric dermatology patients. Pediatr Dermatol 2011; 28: 393-6.
23. Vernon HJ, Lane AT, Weston W,. Comparison of mometasone furoate 01% cream and hydrocortisone 10% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol 1991; 24: 603-7.
24. Wolkerstorfer A, Strobos MA, Glazenburg EJ, et al,. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol 1998; 39: 226-31.
25. Crespi HG,. Topical corticosteroid therapy for children: alclometasone dipropionate cream 005%. Clin Ther 1986; 8: 203-10.
26. Dohil MA, Alvarez-Connelly E, Eichenfield LF,. Fluocinolone acetonide 001% in peanut oil: safety and efficacy data in the treatment of childhood atopic dermatitis in infants as young as 3 months of age. Pediatr Dermatol 2009; 26: 262-8.
27. Eichenfield L, Ellis CN, Fivenson D, et al,. Evaluation of adrenal suppression of a lipid enhanced, topical emollient cream formulation of hydrocortisone butyrate 01% in treating children with atopic dermatitis. Pediatr Dermatol 2007; 24: 81-4.
28. Eichenfield LF, Basu S, Calvarese B, Trancik RJ,. Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis. Pediatr Dermatol 2007; 24: 289-95.
29. Friedlander SF, Hebert AA, Allen DB, Fluticasone Pediatrics Safety Study Group. Safety of fluticasone propionate cream 005% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002; 46: 387-93.
30. Hanifin J,. The role of topical steroids in the treatment of allergic skin disease. Symposium Highlights, 12th Regional Conference of Dermatology, Pattaya, Thailand, 11 May 1996, Conference Programme and Abstracts, 1-2.
31. Hebert AA, Friedlander SF, Allen DB,. Topical fluticasone propionate lotion does not cause HPA axis suppression. J Pediatr 2006; 149: 378-82.
32. Hebert AA III, Desonide Foam Phase Clinical Study Group. Desonide foam 005%: safety in children as young as 3 months. J Am Acad Dermatol 2008; 59: 334-40.
33. Lucky AW, Grote GD, Williams JL, et al,. Effect of desonide ointment, 005%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis 1997; 59: 151-3.
34. Moshang T,. Prednicarbate emollient cream 0-1% in pediatric patients with atopic dermatitis. Cutis 2001; 68: 63-9.
35. Paller AS, Nimmagadda S, Schachner L, et al,. Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. J Am Acad Dermatol 2003; 48: 569-77.
36. Patel L, Clayton PE, Addison GM, et al,. Adrenal function following topical steroid treatment in children with atopic dermatitis. Br J Dermatol 1995; 132: 950-5.
37. Schlessinger J, Miller B, Gilbert RD, et al,. An open-label adrenal suppression study of 01% fluocinonide cream in pediatric patients with atopic dermatitis. Arch Dermatol 2006; 142: 1568-72.
38. Ellison JA, Patel L, Ray DW, et al,. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000; 105: 794-9.
39. Del Rosso J, Friedlander SF,. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol 2005; 53: S50-8.
40. Barbarot S, Bernier C, Deleuran M, et al,. Therapeutic patient education in children with atopic dermatitis: position paper on objectives and recommendations. Pediatr Dermatol 2013; 30: 199-206.
41. Assal J-P, Decchache A, d'Ivernois T-F, et al,. Therapeutic patient education. Continuing Education Programmes for Healthcare Providers in the Field of Prevention of Chronic Diseases. Report of a WHO Working Group. EUR/ICP/QCPH010103. Copenhagen, Denmark: WHO, 1998.
42. Wollenberg A, Ehmann LM,. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol 2012; 24: 253-60.
43. Thaçi D, Reitamo S, Gonzalez Ensenat MA, et al,. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 1348-56.
44. Paller AS, Eichenfield LF, Kirsner RS, et al,. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics 2008; 122: e1210-18.
45. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C,. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011; 164: 415-28.
46. Wollenberg A, Frank R, Kroth J, Ruzicka T,. Proactive therapy of atopic eczema-an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges 2009; 7: 117-21.
47. Schmitt J, Spuls P, Boers M, et al,. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy 2012; 67: 1111-17.